Abstract
Hepatitis B virus (HBV) is the second most common viral infection which poses threat of infection among health care workers and those individuals treated for various debilitated conditions in hospital settings. Patients undergoing haemodialysis are at a greater risk of acquiring HBV infection. Although HBV vaccination has been in use for almost three decades, it is not completely certain about its efficacy in long-term protection. Few studies in the past have emphasized the need for evaluation of anti-HBsAg antibody titers among high risk groups that include patients undergoing haemodialysis. Studies in the past have also noted that few vaccinated group do not respond to HBV vaccine and that few other group of vaccinated individuals develop inadequate antibody titers. The present study evaluated the antibody titers among haemodialysis patients and health care workers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.